Abstract:Abstract Background The global epidemiology of primary liver cancer (PLC), primarily hepatocellular carcinoma (HCC), has evolved significantly in the past decades because of improved control of viral hepatitis and the growing prevalence of metabolic factors. We conducted a quantitative forecast of the incidence and etiology of PLC. Methods Incidence rates of PLC were projected in two endemic Asian countries (Taiwan and Japan) and two Western countries (the United States and United Kingdom) with rigorous cancer registry. The annual incidence of PLC (ICD-10 C22.0) between 1980 and 2013 were obtained from the Taiwan Cancer Registry Database, the Japan National Cancer Center, the US SEER 9 database, Cancer Research UK, and the European Network of Cancer Registry. Incidence rates were projected to year 2035 by an age-period-cohort model with a power link function. The population attributable fractions (PAF) of chronic hepatitis B (HBV), chronic hepatitis C (HCV), alcohol consumption, obesity, and diabetes mellitus (DM) for HCC in Taiwan were projected to 2045. The prevalence of each risk factor was obtained from national surveys and projected inferentially by using a log-linear model or simple linear assumption. The relative risk of each factor was derived from pooled literature data. Results From 2013 to 2035, incidence rates of PLC in Taiwan are estimated to decrease by more than 50% in both men (49.3 to 24.2/100,000) and women (19.7 to 9.2/100,000). In Japan, incidence rates have plateaued in the 1990s, and are expected to continue to decline to 17.0/100,000 for men and 6.3/100,000 for women. Conversely, rates in the UK are projected to increase by more than 30% in both men (13.5 to 18.2/100,000) and women (6.0 to 8.1/100,000). A more modest increase is expected in the US, from 10.2 to 12.5/100,000 for men and 3.3 to 3.5/100,000 for women. In Taiwan, the PAF of HBV, the predominant risk factor of HCC, is predicted to decrease from 54.3% in 2015 to 34.4% in 2045. By 2045, the PAFs of obesity and DM are estimated to reach 11.9% and 15.4%, respectively, the latter similar to that of HCV (15.0%). Conclusion PLC incidence rates are forecast to follow a trend of convergence in four representative countries. Metabolic factors are expected to play increasingly important etiologic role in HCC even in regions currently endemic for viral hepatitis. Citation Format: Emily Han-Chung H. Hsiue, Wei-Cheng Lo, Hsien-Ho Lin, Chih-Hung Hsu, Ann-Lii Cheng. Forecast of the incidence and etiology of liver cancer in Taiwan, Japan, United States, and United Kingdom: toward harmonization of East and West [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 286. doi:10.1158/1538-7445.AM2017-286

Hybrid APASL meeting 2024

Report of Novel Approaches for Portal Hypertension: SNG of the 26th Conference of Asian Pacific Association for the Study of the Liver

APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection.

The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014

Summary and comments of the 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association

[Ten-Year Retrospect of ALPPS in the Treatment of Hepatocellular Carcinoma:An Eternal Concept with Cautious Technologic Choice].

Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus

Contents Vol. 8, 2019

APASL Consensus Statements and Recommendations for Hepatitis C Prevention, Epidemiology, and Laboratory Testing

Contents Vol. 7, 2018

Proceedings of the 28th Annual Congress of the International Liver Transplantation Society

APASL consensus statements and recommendation on treatment of hepatitis C

Abstract 286: Forecast of the Incidence and Etiology of Liver Cancer in Taiwan, Japan, United States, and United Kingdom: Toward Harmonization of East and West

BASHH Annual Conference 2024, Bournemouth, UK, June 17–19 2024

Advances in the 8th Japan-China Hepato-Pancreato-Biliary Symposium

Asian Pacific Association for the Study of the Liver Consensus Statements on the Diagnosis, Management and Treatment of Hepatitis C Virus Infection

Advances in Biliary Tract Cancer Research from the 30th Annual Meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery

The 4th Asia-Pacific Primary Liver Cancer Expert Meeting

APASL Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma-2024

Progress of Hepatic-Biliary-pancreatic Surgery in the 118th Annual Congress of Japan Surgical Society

Advances in hepatopancreatobiliary surgery of the 13th World Congress of the International Hepato-Pancreato-Biliary Association